Pyxis Oncology, Inc. Stock Price, News & Analysis

Pyxis Oncology (Nasdaq: PYXS), a clinical-stage company focused on antibody-drug conjugate therapeutics, has granted stock options to seven new employees under its 2022 Inducement Plan. The grants total 382,518 shares, with 261,268 shares vesting over four years and 121,250 shares vesting on December 31, 2025.

The stock options have a ten-year term and an exercise price of $2.22 per share, matching Pyxis Oncology's closing stock price on September 30, 2025. These grants were made as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4).

Pyxis Oncology (Nasdaq: PYXS), a clinical-stage company focused on developing antibody-drug conjugate therapeutics, has announced its participation in three upcoming conferences in September 2025.

The company's CEO, Dr. Lara S. Sullivan, will participate in fireside chats at the 2025 Cantor Global Healthcare Conference on September 3 and the H.C. Wainwright Global Investment Conference on September 8. Additionally, Pyxis will present at the 2nd Annual ADC and Novel Conjugates Partnering and Investment Summit on September 9.

Webcasts for the investor conference presentations will be available on the company's investor relations website.

Pyxis Oncology (Nasdaq: PYXS) reported Q2 2025 financial results and provided updates on its clinical programs. The company's lead antibody-drug conjugate (ADC) candidate, micvotabart pelidotin (MICVO), is advancing in clinical trials with preliminary data expected in H2 2025 and H1 2026.

Key financial highlights include $90.4 million in cash and investments, providing runway into H2 2026. Q2 revenues were $2.8 million from a milestone payment from Simcere, with a net loss of $18.4 million ($0.30 per share). R&D expenses increased to $17.1 million, while G&A expenses decreased to $5.4 million.

The company is progressing with two key clinical trials: a Phase 1 monotherapy study for head and neck cancer and a Phase 1/2 combination study with KEYTRUDA®, both showing promising potential in treating advanced solid tumors.

Pyxis Oncology (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation antibody-drug conjugate therapeutics, has announced the granting of inducement stock options to four new employees. The company's Compensation Committee approved options to purchase 246,238 shares of common stock under the 2022 Inducement Plan.

The stock options are structured in two tranches: 181,238 options vest over four years with 25% vesting after one year and the remainder monthly over 36 months, while 65,000 options vest fully on December 31, 2025. All options have a ten-year term and an exercise price of $1.10 per share, matching Pyxis Oncology's closing stock price on June 30, 2025.

Pyxis Oncology (NASDAQ: PYXS) reported Q1 2025 financial results and provided updates on its lead candidate micvotabart pelidotin (MICVO). The company presented promising preclinical data demonstrating MICVO's unique three-pronged mechanism of action, showing anti-tumor activity through direct tumor killing, bystander effect, and immunogenic cell death. Key upcoming milestones include preliminary data from Phase 1 trials in H2 2025 for MICVO monotherapy in head and neck cancer patients and combination therapy with pembrolizumab. Financially, Pyxis reported $106.9 million in cash and investments, with runway extending into H2 2026. Q1 2025 saw a net loss of $21.2 million ($0.35 per share), with R&D expenses at $17.0 million and G&A expenses at $5.9 million. The company remains focused on developing treatments for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) and other advanced solid tumors.

Pyxis Oncology (NASDAQ: PYXS), a clinical-stage company focused on developing next-generation ADC therapeutics for difficult-to-treat cancers, has announced its participation in two upcoming investor conferences. The company's President, CEO, and CMO, Dr. Lara S. Sullivan, will engage in fireside chats at:

- The 2025 RBC Capital Markets Global Healthcare Conference in New York on May 21 at 2:05 p.m. ET

- The Jefferies Global Healthcare Conference in New York on June 5 at 4:55 p.m. ET

Investors can access live webcasts and replays of both presentations through the Events & Presentations page in the Investor Relations section of Pyxis Oncology's website.

Pyxis Oncology (NASDAQ: PYXS) presented promising preclinical results for micvotabart pelidotin (MICVO), their first-in-concept antibody-drug conjugate targeting Extradomain-B Fibronectin. The data, presented at AACR 2025, demonstrated:

• 45% of PDX models showed strong to very strong tumor growth inhibition
• Complete responses were observed across multiple tumor indications
• The drug was well-tolerated at 3mg/kg dosing
• Combination therapy with anti-PD-1 achieved 91% tumor growth inhibition with complete response in 9/15 animals

MICVO's three-pronged mechanism of action includes direct tumor killing, bystander effect, and immunogenic cell death. The drug is currently in Phase 1 trials as both monotherapy and in combination with KEYTRUDA for advanced solid tumors.

Pyxis Oncology (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics for difficult-to-treat cancers, has announced its participation in the upcoming Stifel 2025 Virtual Targeted Oncology Forum. Dr. Lara S. Sullivan, who serves as President, CEO and Chief Medical Officer, will engage in a fireside chat on Wednesday, April 9, 2025, at 11:30 a.m. ET.

The company will also conduct one-on-one investor meetings during the event. Investors and interested parties can access both the live webcast and replay of the fireside chat through the Events & Presentations page in the Investor Relations section of Pyxis Oncology's website at ir.pyxisoncology.com.

Pyxis Oncology (NASDAQ: PYXS) announced new preclinical data for micvotabart pelidotin (MICVO), their first-in-concept antibody-drug conjugate targeting EDB+FN in the tumor microenvironment. The data will be presented at AACR 2025 in Chicago.

Key highlights include:

• Patient-derived xenograft mouse models showed gene signatures associated with MICVO efficacy
• Combination of MICVO analog with anti-PD-1 therapy demonstrated enhanced tumor regression
• Phase 1 studies showed significant tumor regression across multiple tumor types

The company is advancing MICVO in clinical trials:

• Phase 1 monotherapy expansion for recurrent/metastatic head and neck cancer with preliminary data expected in 2H2025 and 1H2026
• Phase 1/2 combination study with Keytruda® with preliminary data expected in 2H2025

MICVO has received Fast Track Designation from the FDA for treating adult patients with recurrent/metastatic head and neck squamous cell carcinoma after platinum-based chemotherapy and anti-PD-(L)1 therapy.